Status:
COMPLETED
Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention
Lead Sponsor:
University of Arizona
Conditions:
Acute Coronary Syndrome
Coronary Artery Disease
Eligibility:
FEMALE
45+ years
Brief Summary
Plavix (clopidogrel) is a drug that is approved by the FDA (Food and Drug Administration) to reduce the risk of having another heart attack by preventing platelets (blood cells that are important in f...
Eligibility Criteria
Inclusion
- All females age 45 or greater, presenting to University of Arizona Medical Center South Campus or University Campus Cardiology service with a history of ACS
- Hispanics will be defined via self-reporting as having both parents of Latino descent
- Currently taking clopidogrel
Exclusion
- Taking any of the following antiplatelet drugs:
- Prasugrel (Effient)
- Ticagrelor (Brilinta)
- Ticlopidine (Ticlid)
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01796873
Start Date
January 1 2012
End Date
April 1 2014
Last Update
August 22 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona Medical Center South Campus
Tucson, Arizona, United States, 85713
2
University of Arizona Medical Center University Campus
Tucson, Arizona, United States, 85724